Strategic Partnership with Biomimetic Innovations
Sanara MedTech Inc. has taken a significant step forward by establishing an exclusive license and distribution agreement with Biomimetic Innovations Ltd, alongside a substantial minority investment. This partnership positions Sanara to enhance its groundbreaking surgical solutions in the U.S. market.
Investment Details
Sanara is committing up to €8.0 million in cash to Biomimetic Innovations, in exchange for about 12.5% of the company’s equity. The initial payment of €4.0 million has been made, with another €4.0 million contingent on meeting certain milestones. This investment not only reflects Sanara's confidence in Biomimetic's innovative solutions but also strengthens its strategic foothold in the medical device industry.
Exclusive Distribution of OsStic
Under the agreement, Sanara will obtain exclusive rights to market and distribute OsStic Synthetic Injectable Structural Bio-Adhesive Bone Void Filler in the United States. This innovative product is designed for fracture management and comes with a unique internal fixation technology that enhances its application during surgeries.
Breakthrough Device Designation
OsStic recently received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA), indicating its potential to significantly improve treatment outcomes for patients. The FDA designation paves the way for faster regulatory reviews, allowing Sanara to introduce the product to the U.S. market sooner.
Leadership Insights on OsStic
Ron Nixon, CEO of Sanara, expressed excitement about this collaboration, emphasizing that OsStic represents a new frontier in the treatment of periarticular fractures, which affect thousands of patients annually in the U.S. This innovative solution promises to enhance the overall surgical experience for both healthcare providers and patients alike.
Superior Technology Features
Dr. Thomas Russell, Chief Medical Officer of PBC Biomed, highlighted the superiority of OsStic over traditional bone substitutes. Unlike conventional materials, OsStic is engineered to integrate effectively with bone, providing much-needed mechanical support during the healing process. This advancement sets a new standard for addressing critical clinical needs in orthopedic surgery.
Joint Commitment to Patient Wellness
According to Paul Burke, Managing Partner of PBC Biomed, the partnership aims to enhance patient well-being through innovative medical technologies. With Sanara's established market presence and expertise, the collaboration is expected to yield transformative solutions that improve surgical outcomes.
Future Outlook for Sanara MedTech
As Sanara MedTech Inc. continues to expand its product portfolio and market capabilities, this partnership with Biomimetic Innovations is pivotal. The integration of OsStic and other advanced technologies underscores Sanara’s commitment to delivering innovative solutions that significantly improve patient care.
Furthermore, Sanara is constantly pursuing strategic partnerships to drive innovations from conception through to clinical development, always with the aim of enhancing patient outcomes while reducing healthcare costs.
Frequently Asked Questions
What is the significance of the agreement with Biomimetic Innovations?
This partnership allows Sanara to market and distribute OsStic in the U.S., enhancing its surgical product offerings.
How much has Sanara invested in Biomimetic Innovations?
Sanara has committed up to €8.0 million, acquiring approximately 12.5% of Biomimetic Innovations.
What is OsStic?
OsStic is an injectable structural bio-adhesive bone void filler designed for managing fractures in surgical procedures.
What is the Breakthrough Device Designation?
This designation by the FDA facilitates faster regulatory reviews for devices that show promise in treating or diagnosing serious conditions.
How does Sanara plan to utilize this partnership?
Sanara aims to integrate OsStic into its existing product lines to improve patient outcomes and enhance the surgical experience.
